Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1 By Ogkologos - July 1, 2025 444 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KOMET study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR New option to treat advanced oesophageal cancer approved for NHS in... August 11, 2021 ΚΑΡΚΙΝΟΣ ΤΟΥ ΝΕΦΡΟΥ February 10, 2019 Combination Chemo Helps People with Leiomyosarcoma Live Longer October 2, 2024 Post-Mastectomy Boutique Set to Close After 12 Years, As Owner Has... March 12, 2019 Load more HOT NEWS GreaterGood Is Helping UMN Fight Social Injustice with Scholarship for Underrepresented... TAT 2021 Honorary Award: A Recognition in Cancer Drug Development to... Man Who Lost Wife to Breast Cancer Wants to Donate Her... Mirvetuximab Soravtansine-gynx Shows a Significant Benefit Over Chemotherapy in Women with...
